
|Videos|September 11, 2017
Significance of the Phase III FLAURA Study in EGFR+ NSCLC
Author(s)Joshua Bauml, MD
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the randomized phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non-small cell lung cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































